Engineered immune cells take on tough lung cancer
NCT ID NCT07480213
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new treatment called CAR-NK cells, which are immune cells engineered to recognize and attack cancer. The trial enrolls 60 adults with small cell lung cancer that has come back or not responded to standard treatments. Participants receive the cells along with chemotherapy to prepare the body. The goal is to find a safe dose and see if the therapy can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EB-DART-NK01 (DLL3/CD56 CAR-NK cells) plus lymphodepleting chemotherapy (fludarabine + cyclophosphamide)
- What this could lead to
- If successful, this could point toward a new treatment option for people with hard-to-treat small cell lung cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early phase 1/2 trial with only 60 participants, so results may not apply to everyone. The therapy is experimental and may cause serious side effects, including immune reactions or organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY SCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at stubborn lung cancer
- Could a hidden nerve condition be more common in lung cancer than we think?
- Can a targeted drug combo outperform standard chemo for tough lung cancer?
- Can a gentler drug trio tame small cell lung cancer in older patients?
- Experimental combo aims to tackle Treatment-Resistant cancers
- New drug cocktail aims to shrink tough lung cancers